GlassScriptPhysician profile
Elaine M Cadorette
NPI 1164751152
$8,280.31
in general payments reported to CMS, 2019-2025
22 companies · $32.11 in 2025
The $32.11 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,399 · 2022: $2,082 · 2023: $3,257 · 2024: $1,511 · 2025: $32.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,640 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,639.89 |
| Education | $159.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,133.60 | 2021-2024 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,800.32 | 2021-2024 | Dupixent |
| Genzyme Corporation | $1,705.55 | 2021-2024 | |
| Glaxosmithkline, LLC. | $843.20 | 2021-2025 | Trelegy Ellipta, Nucala |
| Blueprint Medicines Corporation | $339.72 | 2021-2023 | Ayvakit |
| Csl Behring | $327.65 | 2021-2024 | Haegarda, Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $203.28 | 2021-2023 | Takhzyro |
| Abbvie INC. | $166.87 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $144.45 | 2021-2024 | |
| Biocryst US Sales Co., LLC | $122.63 | 2022 | |
| Amgen INC. | $88.61 | 2022-2023 | Tezspire |
| Phadia US INC. | $83.20 | 2022 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $52.56 | 2021 | |
| Pfizer INC. | $31.67 | 2021-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $28.84 | 2021 | |
| Pharming Healthcare, INC. | $26.83 | 2023 | Ruconest |
| Aimmune Therapeutics, INC. | $24.91 | 2022 | |
| Grifols USA, LLC | $22.43 | 2022 | |
| Horizon Therapeutics Plc | $21.58 | 2022 | |
| Merck Sharp & Dohme LLC | $17.07 | 2022 | |
| Incyte Corporation | $15.35 | 2023 | Opzelura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elaine Cadorette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.